Kaplan JM - Search Results

1

Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens.

Perricone MA, Claussen KA, Smith KA, Kaplan JM, Piraino S, Shankara S, Roberts BL. Perricone MA, et al. Among authors: kaplan jm. Mol Ther. 2000 Mar;1(3):275-84. doi: 10.1006/mthe.2000.0029. Mol Ther. 2000. PMID: 10933943 Free article.

2

Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes.

Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, Kaplan JM. Perricone MA, et al. Among authors: kaplan jm. J Immunother. 2004 Jul-Aug;27(4):273-81. doi: 10.1097/00002371-200407000-00003. J Immunother. 2004. PMID: 15235388

3

Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.

Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL. Kaplan JM, et al. J Immunol. 1999 Jul 15;163(2):699-707. J Immunol. 1999. PMID: 10395660

4

Inhibitory effect of cystic fibrosis sputum on adenovirus-mediated gene transfer in cultured epithelial cells.

Perricone MA, Rees DD, Sacks CR, Smith KA, Kaplan JM, St George JA. Perricone MA, et al. Among authors: kaplan jm. Hum Gene Ther. 2000 Sep 20;11(14):1997-2008. doi: 10.1089/10430340050143426. Hum Gene Ther. 2000. PMID: 11020799

5

Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies.

Guyre CA, Gomes D, Smith KA, Kaplan JM, Perricone MA. Guyre CA, et al. Among authors: kaplan jm. J Immunol Methods. 2008 Apr 20;333(1-2):51-60. doi: 10.1016/j.jim.2008.01.002. Epub 2008 Feb 11. J Immunol Methods. 2008. PMID: 18314132

6

Solid-phase epitope recovery: a high throughput method for antigen identification and epitope optimization.

Lawendowski CA, Giurleo GM, Huang YY, Franklin GJ, Kaplan JM, Roberts BL, Nicolette CA. Lawendowski CA, et al. Among authors: kaplan jm. J Immunol. 2002 Sep 1;169(5):2414-21. doi: 10.4049/jimmunol.169.5.2414. J Immunol. 2002. PMID: 12193709

7

Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.

Siders WM, Shields J, Garron C, Hu Y, Boutin P, Shankara S, Weber W, Roberts B, Kaplan JM. Siders WM, et al. Among authors: kaplan jm. Leuk Lymphoma. 2010 Jul;51(7):1293-304. doi: 10.3109/10428191003777963. Leuk Lymphoma. 2010. PMID: 20377308

8

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, Shankara S, Roberts BL, Kaplan JM. Rao SP, et al. Among authors: kaplan jm. PLoS One. 2012;7(6):e39416. doi: 10.1371/journal.pone.0039416. Epub 2012 Jun 25. PLoS One. 2012. PMID: 22761788 Free PMC article.

9

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. Hu Y, et al. Among authors: kaplan jm. Immunology. 2009 Oct;128(2):260-70. doi: 10.1111/j.1365-2567.2009.03115.x. Immunology. 2009. PMID: 19740383 Free PMC article.

10

Immune status following alemtuzumab treatment in human CD52 transgenic mice.

Turner MJ, Lamorte MJ, Chretien N, Havari E, Roberts BL, Kaplan JM, Siders WM. Turner MJ, et al. Among authors: kaplan jm. J Neuroimmunol. 2013 Aug 15;261(1-2):29-36. doi: 10.1016/j.jneuroim.2013.04.018. Epub 2013 Jun 4. J Neuroimmunol. 2013. PMID: 23759318 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

257 results

Search Page

Filters